Stock Monitor: A. Schulman Post Earnings Reporting
LONDON, UK / ACCESSWIRE / January 10, 2018 / Active-Investors.com has just released a free research report on ChromaDex Corp. (NASDAQ: CDXC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=CDXC as the Company's latest news hit the wire. On January 08, 2018, the Company declared that it has launched TRU NIAGEN™ in Singapore with Watsons, its retail partner. Watsons introduced TRU NIAGEN™ in stores in Singapore and online on January 04, 2018, with launch event scheduled for January 10, 2018. TRU NIAGEN™ is the US made dietary supplement. Register today and get access to over 1000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for A. Schulman, Inc. (NASDAQ: SHLM), which also belongs to the Basic Materials sector as the Company ChromaDex. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=SHLM
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ChromaDex most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=CDXC
TRU NIAGEN™ has Proven Effectiveness in Raising NAD+ Levels
Irene Lau, Chief Operating Officer of Watsons Singapore, stated that Singapore is feeling the impact of a rapidly aging population and that comes with a set of needs to lead healthier lives. Watsons wants to be able to meet that need and bring market-leading health products that can better the lives of Singaporeans. Irene added that TRU NIAGEN™ provides nutritional support and has proven effectiveness in raising levels of NAD+ which may slow cell dysfunction and help achieve optimal health.
ChromaDex Partnered with Watsons to Launch TRU NIAGEN™ in Hong Kong
In September 2017, ChromaDex entered into a partnership with Hong Kong based retailer, A.S. Watson, for the launch of the US made TRU NIAGEN™ dietary supplement in Asia. Watsons launched TRU NIAGEN™ in over 100 stores in Hong Kong and online in eStore. Watsons planned to launch TRU NIAGEN™ in additional retail outlets in Macau in the near future.
ChromaDex has Conducted Various Studies and Human Clinical Trials Supporting the Safety and Efficacy of TRU NIAGEN™
ChromaDex has invested millions in analytical research, toxicology studies, and human clinical trials supporting the safety and efficacy of TRU NIAGEN™. The Company has initiated over 120 collaborative studies with leading universities and research institutions such as the National Institute of Aging, MIT, and the Scripps Research Institute. Research undertaken by the Company indicates that anti-aging benefits of TRU NIAGEN™ include increased metabolism and energy production in every cell, promotion of healthy mitochondrial function, which is an important component of human aging and increased sirtuin activation, improving mitochondrial activity to help defend against cellular damage due to free radicals.
About TRU NIAGEN™
TRU NIAGEN™ is a branded dietary supplement brought to market by key nicotinamide riboside (NR) innovator and patent holder, ChromaDex. NIAGEN® nicotinamide riboside, a cutting-edge form of vitamin B3, also supplied by ChromaDex, is the feature ingredient in TRU NIAGEN™. Published research suggests that it is clinically proven to boost NAD+ (nicotinamide adenine dinucleotide) levels, which decline with age. Only NIAGEN® nicotinamide riboside has Generally Recognized as Safe (GRAS) status and a New Dietary Ingredient Notification (NDIN), both reviewed by FDA.
The body converts NR into NAD+ which is an essential molecule found in every living cell. NAD+ activates cellular metabolism and energy production within the cell's power stations, the mitochondria. Maintenance of sufficient levels of NAD+ is key to cellular energy metabolism and mitochondrial function.
About ChromaDex Corp.
Founded in 1999, ChromaDex is an integrated, global nutraceutical company that leverages its complementary business units to discover, acquire, develop, and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company is headquartered in Irvine, California.
About Watsons Singapore
Watsons is Asia's leading health and beauty retailer, currently operating over 3,500 stores and more than 900 pharmacies in 12 Asian and European markets, including China (Mainland China, Hong Kong, Taiwan, and Macau), Singapore, Thailand, Malaysia, the Philippines, Korea, Indonesia, Turkey, and Ukraine. Watsons is Singapore's leading beauty and health retailer with more than 100 stores located islandwide.
Stock Performance Snapshot
January 09, 2018 - At Tuesday's closing bell, ChromaDex's stock rose 1.29%, ending the trading session at $6.30.
Volume traded for the day: 233.67 thousand shares.
Stock performance in the last month - up 0.80%; previous three-month period - up 38.77%; past twelve-month period - up 105.88%; and year-to-date - up 7.14%
After yesterday's close, ChromaDex's market cap was at $336.23 million.
The stock is part of the Basic Materials sector, categorized under the Chemicals - Major Diversified industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
